A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells: SLAS Discovery

Harald Hundsberger, Anita Koppensteiner, Elisabeth Hofmann, Doris Ripper, Maren Pflüger, Valerie Stadlmann, Christian Theodor Klein, B. Kreiseder, M. Katzlinger, Andreas Eger, Florian Forster, A. Missbichler, Christoph Wiesner

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

Abstract

Celiac disease (CD) is a chronic inflammatory condition caused by the ingestion of gliadin-containing food in genetically susceptible individuals. Undigested peptides of gliadin exert various effects, including increased intestinal permeability and inflammation in the small intestine. Although many therapeutic approaches are in development, a gluten-free diet is the only effective treatment for CD. Affecting at least 1% of the population in industrialized countries, it is important to generate therapeutic options against CD. Here, we describe the establishment of a high-throughput screening (HTS) platform based on AlphaLISA and electrical cell–substrate impedance sensing (ECIS) technology for the identification of anti-inflammatory and barrier-protective compounds in human enterocytes after pepsin-trypsin-digested gliadin (PT-gliadin) treatment. Our results show that the combination of these HTS technologies enables fast, reliable, simple, and label-free screening of IgY antibodies against PT-gliadin. Using this platform, we have identified a new chicken anti-PT-gliadin IgY antibody as a potential anti-CD agent.
OriginalspracheEnglisch
Seiten (von - bis)1035-1043
Seitenumfang9
FachzeitschriftSLAS Discovery
Jahrgang22
Ausgabenummer8
DOIs
PublikationsstatusVeröffentlicht - 8 Sep. 2017

Fingerprint

Untersuchen Sie die Forschungsthemen von „A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells: SLAS Discovery“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren